SSSashrik Sribhashyam

Sashrik Sribhashyam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sashrik Sribhashyam has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association Between Anesthesia Modality and Registry-Recorded Adverse Events in Knee Arthroscopy: A National Database Study

    by Sashrik Sribhashyam, Suhas R. Velichala, Aadi Sharma, Brady Ernst, Benjamin P. Cassidy, Conor N. O’Neill, Omar A. Protzuk

    Background/Objectives: This study evaluated associations between anesthesia modality and adverse events after elective knee arthroscopy. Methods: This retrospective cohort study evaluated adults undergoing elective knee arthroscopy in the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) from 2011–2023. Principal anesthesia was classified as general, monitored anesthesia care (MAC), regional, or neuraxial. We used generalized overlap weighting to balance baseline characteristics within procedure-year groups containing all four anesthesia categories. The primary outcome combined registry-recorded perioperative and 30-day adverse events. We compared each non-general category with general anesthesia using bootstrap confidence intervals and Holm-adjusted tests. Results: Of 168,626 complete cases, 138,680 entered the primary analysis, with 1883 adverse events. Weighted risks were 1.41% for general, 1.55% for MAC, 1.27% for regional, and 1.43% for neuraxial anesthesia. Risk differences versus general, in percentage points, were MAC 0.14 (95% CI, −0.33 to 0.61), regional −0.14 (−0.91 to 0.62), and neuraxial 0.02 (−0.51 to 0.54). All three Holm-adjusted p-values were 1.00. Regional anesthesia contributed only 11 events. A full-cohort Firth analysis included 2450 events, and all anesthesia odds-ratio intervals included one. Conclusions: No statistically significant association was detected, but the confidence intervals do not establish equivalent risks. Findings apply to the population represented in the weighted analysis. Principal codes do not establish exclusive techniques or airway management. Residual confounding, missing-data selection, and unavailable recovery outcomes limit interpretation.

  • Post-operative complications following shoulder stabilization for primary versus recurrent anterior shoulder dislocation: a national database study

    by Andrew K. Chow, Sashrik Sribhashyam, Suhas Rao Velichala, Matthew S. Smith, Benjamin P. Cassidy, Jennifer Vanderbeck, Jonathan F. Dickens, James Satalich

  • Open Access

    Short-term outcomes following reconstruction or direct repair of the ulnar collateral ligament

    by Sashrik Sribhashyam, Grayson M. Talaski, Shahabeddin Yazdanpanah, Matthew S. Smith, Andrew S. Cuthbert, Jennifer L. Vanderbeck, J. Brett Goodloe

  • Open Access

    Primary vs. revision total elbow arthroplasty: an updated analysis of short-term complications and associated factors

    by James R. Satalich, Matthew S. Smith, Sashrik Sribhashyam, Jenna L. Hughes, Mohini Johri, Benjamin P. Cassidy, Jennifer L. Vanderbeck, Shahabeddin Yazdanpanah

  • Open Access

    Revision Total Ankle Arthroplasty Using the INVISION Modular Implant System: A Systematic Review and Meta-Analysis

    by Shahabeddin Yazdanpanah, Braeden R. Gooch, Sashrik Sribhashyam, John W. Cyrus, Benjamin P. Cassidy, Samuel B. Adams, Albert T. Anastasio, Conor N. O’NEill

    Background: Globally, rising rates of ankle arthritis have largely driven increases in total ankle arthroplasty (TAA) and revision TAA (rTAA). INVISION (Wright Medical/Stryker) is a novel modular implant system designed for addressing rTAA-associated challenges; however, clinical outcomes remain limited. Therefore, the purpose of this systematic review is to synthesize the available INVISION rTAA literature to evaluate implant survivorship and complication rates. Methods: A PROSPERO-preregistered query of PubMed/MEDLINE, Embase, Cochrane, CINAHL, and Web of Science was performed on August 18, 2025, to identify INVISION-using rTAA studies. Quality was assessed using the Methodological Index for Non-Randomized Studies (MINORS). Extractions included demographics and operative outcomes. Statistics included frequency-weighted means (FWMs) and meta-analyses. Results: Five retrospective studies were included (mean MINORS = 10.2 ± 0.8; n = 100; FWM age = 64.0 ± 8.4 years; follow-up = 2.8 ± 1.2 years; 56% male; body mass index = 30.5 ± 5.5 kg/m 2 ; time-to-revision = 4.5 ± 2.5 years). Tibial-talar implant permutations were INVISION-INVISION (25%), INVISION-INBONEII (19%), and INBONEII-INVISION (56%). Patients underwent an average of 1.8 additional procedures to rTAA: frequently medial malleolus fixation (21.8%) and hardware removal (17.3%). Pooled implant survivorship was 88%. Complication rates varied (0%-39.3%), and the all-cause rTAA pooled reoperation rate was 21%, driven primarily by aseptic loosening (38.1%) and infection (28.6%). The pooled re-revision rate was 11%. Meta-analyses revealed no significant differences in either all-cause reoperation or re-revision risk when comparing INVISION-INVISION to any other implant permutations. Conclusion: INVISION rTAA demonstrated early survivorship and complication rates that should be interpreted cautiously given retrospective study designs, high heterogeneity, “very low” GRADE outcome certainty, and limited follow-up duration. Aseptic loosening and infection remain the predominant drivers of reoperation and re-revision. No significant differences in these risks were detected across implant permutations. Future longitudinal, comparative studies are needed.

  • Open Access

    Short-term complications following distal humerus open reduction and internal fixation

    by Sashrik Sribhashyam, Grayson M. Talaski, Shahabeddin Yazdanpanah, Carl Edge, Matthew S. Smith, Andrew S. Cuthbert, Jennifer L. Vanderbeck


  • Revision rates of porous-coated versus grit-blasted femoral stems in cementless total hip arthroplasty: A systematic review

    by Sashrik Sribhashyam, Robert S. Chin, Aadi Sharma, Brady Ernst, Matthew S. Smith, Benjamin Cassidy, John Cyrus, Jibanananda Satpathy


  • Open Access

    Structure based approaches on fentanyl template to design novel mu opioid modulators

    by Rohini Ople, Haoqing Wang, Qiongyu Li, Ben Polacco, Sarah Bernhard, Kevin Appourchaux, Sashrik Sribhashyam, Shainnel Eans, Ruth Huttenhain, Jay McLaughlin, et al.

    ID 52769 Poster Board 538 Opioids are used for the treatment of acute to severe pain. Usage of opioids also produces liabilities like respiratory depression and addiction, which in combination with illicit use of fentanyl and designer analogs has contributed to the opioid epidemic. Most approaches to design safer opioids have been restricted to targeting the orthosteric binding sites. We have recently reported a novel strategy to design functionally selective opioids by targeting the sodium binding allosteric site in the mu opioid receptor (MOR). The lead ligand C6 guano engages a key residue Asp2.50 in the sodium site through a salt bridge with a guanidine group in the ligand. C6 guano shows MOR dependent antinociception with reduced adverse effects seen with clinically used opioids (Faouzi et al., Nature 2023, 613, 767–774). While representing a significant advance in the design of opioids, C6 guano is supraspinally active because of the polar and charged guanidine group. Using the cryo-EM structure of C6 guano bound to MOR, we designed second generation analogs to optimize the systemic activity of C6 guano. Characterization of analogs led to the identification of a fentanyl-derived compound named RO-76 which in TRUPATH assays showed reduced efficacy at all Gi/o/z subtypes and no measurable efficacy at β-arrestin-1/2 and labelled unique transducers in APEX2 proximity labeling assays. Unlike C6 guano which showed direct engagement of the sodium site, RO-76 interacted with the sodium site residues through a water in cryo-EM of RO-76 bound to MOR-Gi complex. Previous high-resolution structures of MOR have predicted the presence of a polar cavity in the sodium binding pocket, but these waters have not been rationally targeted before at MOR or other GPCRs to the best of our knowledge. In mice, the drug was systemically active in tail withdrawal assays, and showed reduced respiratory depression and conditioned place preference compared to morphine. In summary, we envision that targeting the sodium binding site may be a potential avenue to both probe the role of the sodium site in MOR function as well as development of a new class of analgesics in the near future. Support and sponsors: Center for Clinical Pharmacology University of Health Sciences and Pharmacy at St. Louis National Institute of Drug Abuse